Touyun Biotech Group Limited announced a plan to replace its current bye-laws with a second amended and restated version. Key points are as follows:

• Scope of revisions: The new bye-laws will incorporate four principal changes—(1) provisions for hybrid shareholder meetings and electronic voting, (2) alignment with the expanded paperless listing regime and electronic dissemination of corporate communications, (3) rules covering treasury shares, and (4) preparatory clauses for the future uncertificated securities market, alongside general housekeeping updates.

• Approval process: The amendments will be put to shareholders through a special resolution at the 5 June 2026 Annual General Meeting. If approved, the updated bye-laws take effect immediately after the AGM, superseding the existing version.

• Shareholder materials: A circular containing the full text of the proposed bye-laws, AGM notice and proxy form will be dispatched in due course. Post-approval, the final document will be available on both the Hong Kong Stock Exchange and company websites.

• Board position: The board views the revisions as beneficial for the company and its shareholders, ensuring compliance with recent Listing Rules updates and facilitating future electronic market infrastructure.

• Governance: As of the announcement date, Touyun Biotech’s board comprises Chairman and Executive Director Wang Liang, Executive Director Du Dong, three non-executive directors, and three independent non-executive directors.